News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
March, 2025
March 2025
M T W T F S S
 12
3456789
10111213141516
17181920212223
24252627282930
31  
Hagop Kantarjian: In this phase 2 study, a convenient, fully-oral regimen was effective and safe in an older/unfit population with acute myeloid leukemia
Hagop Kantarjian/mdanderson.org
Mar 10, 2024, 20:49

Hagop Kantarjian: In this phase 2 study, a convenient, fully-oral regimen was effective and safe in an older/unfit population with acute myeloid leukemia

 

Hagop Kantarjian, a Professor and Chair of the Department of Leukemia at The University of Texas MD Anderson Cancer Center, recently posted on X:

“In this phase 2 study, a convenient, fully-oral regimen was effective and safe in an older/unfit population with acute myeloid leukemia. ”

Source: Hagop Kantarjian/X

Acute Myeloid Leukemia AML cancer cedazuridine decitabine fully-oral regimen Hagop Kantarjian Hematology older/unfit population OncoDaily Oncology phase 2 study venetoclax
Special Coverage
Blog
Mar 29, 2025, 13:29
Bilal Awad: My Blog about Colorectal Cancer Awareness Month - A Call to Action
Blog
Mar 29, 2025, 13:09
Tedros Adhanom Ghebreyesus: The 2nd WHO Global Conference on Air Pollution and Health
Blog
Mar 29, 2025, 12:57
Hidehito Horinouchi: COCOON trial on preventing dermatologic adverse events in EGFR-mutant NSCLC
Blog
Mar 29, 2025, 12:32
Flavio Rocha: Inspiring presidential address by Ronald de Matteo at SSO2025
Blog
Mar 29, 2025, 12:27
Catherine Alix-Panabières: Honored to moderate at ESMO European Lung Cancer Congress 2025
Blog
Mar 29, 2025, 12:06
Loay Kassem: Who should be the first author of the manuscript?
Insight
Mar 29, 2025, 12:00
Surgery may not be necessary to treat invasive breast cancer
Blog
Mar 29, 2025, 11:58
Uta Schmidt-Straßburger: Insights from the Digital Health Innovation Forum
Radiotherapy
Mar 29, 2025, 11:54
Is Brachytherapy Right for You? The Science, Benefits, and Drawbacks Explained
Societies
Mar 29, 2025, 11:36
Patient-Reported Outcomes: ASCO Guideline is now available for Open Comment
Blog
Mar 29, 2025, 11:26
Insights from Axios' 4th Annual What's Next Summit by Lisa A. Lacasse
Blog
Mar 29, 2025, 11:25
Join Christine Iacobuzio-Donahue and Christine Lovly for AACR25 Professional Advancement Session: Cancer Discovery